Unfortunately, the original version of this article \[[@CR1]\] contained an error due to a typographical error in the computer code used. This meant the percentage improvement over baseline of the endpoints CMTNS, ONLS, 9HPT and DML was slightly increased. Therefore some of the values in Tables [3](#Tab1){ref-type="table"}, [4](#Tab2){ref-type="table"}, Additional file [4](#MOESM1){ref-type="media"}: Table S4 and Fig. [4](#Fig1){ref-type="fig"} are incorrect.Table 3Response to PXT3003 on efficacy outcomes in treatment groups, with comparisons of active doses versus Placebo (Full Analysis Set, *n* = 80)Mean % of improvementPXT3003 LD versus PlaceboPXT3003 ID versus PlaceboPXT3003 HD versus PlaceboDose-effectPlaceboPXT3003 LDPXT3003 IDPXT3003 HDEstimate*P*-valueEstimate*P*-valueEstimate*P*-valueCorrelation*P*-value(*n* = 19)(*n* = 21)(*n* = 21)(*n* = 19)CMTNS−0.25 (17.3)−3.8 (20.4)−5.8 (17.7)**5.2 (12.5)**−2.6 (−11.9;7.6)0.67−3.1 (−11.0;5.4)0.745.5 (−3.4;15.2)0.160.540.30ONLS−11.8 (33.7)−12.7 (31.7)1.2 (16.7)**6.8 (18.2)**−3.9 (−14.2;7.6)0.726.9 (−3.8;18.8)0.1514.4 (0.55;30.2)0.043\*0.280.006\*6MWT (m)9.0 (8.3)6.2 (8.3)6.4 (9.4)**9.9 (6.9)**−2.4 (−6.2;1.5)0.85−2.4 (−6.6;2.0)0.820.7 (−3.2;4.7)0.380.110.169HPT (s)3.6 (10.9)−2.5 (12)4.4 (9.5)**6.1 (10.6)**−4.6 (−10.3;1.5)0.89−0.2 (−5.3;5.2)0.520.3 (−5.7;6.6)0.470.150.092Ankle Dorsiflexion (Nm)20.2 (88.4)−3.6 (43.0)**81.5 (369.6)**20.4 (64.1)−4.0 (−21.7;17.8)0.6311.4 (−15.4;46.8)0.268.2 (−13.8;35.9)0.280.110.16Grip (kg)9.9 (24.2)1.3 (15.6)4.7 (12.5)**11.7 (18.1)**−7.1 (−15.6;2.1)0.90−3.6 (−11.8;5.4)0.751.6 (−7.7;11.9)0.390.120.15CMAP (milliV)34.4 (62.0)1.4 (38.7)22.9 (62.6)**64.2 (208.5)**−25.1 (−44.8;1.5)0.94−9.2 (−27.3;13.5)0.77−5.1 (−27.1;23.6)0.63−0.0010.50MCV (m/s)3.7 (8.5)3.0 (11.5)5.7 (12.3)**9.0 (17.6)**−1.0 (−6.5;4.9)0.610.5 (−4.8;6.2)0.442.8 (−3.4;9.4)0.230.110.18DML (ms)−0.33 (8.7)0.33 (16.1)**8.3 (18.1)**5 (15.2)3.4 (−4.3;11.7)0.2413.8 (4.2;24.3)0.009\*8.0 (0.59;16.0)0.038\*0.210.035\*SNAP (microV)12.4 (121.7)11.5 (88.2)**23.3 (128.4)**5.2 (69.0)−1.2 (−42.9;71.0)0.528.7 (−31.2;71.6)0.3813.9 (−24.1;71.0)0.290.090.30SCV (m/s)3.4 (11.0)5.3 (11.2)29.5 (63.4)**30.5 (10.0)**1.5 (−5.8;9.4)0.3617.5 (−5.5;46.2)0.11†26.6 (15.5;38.8)0.00037\*0.420.01\*Data are mean % (s.d.) of improvement for each treatment group. Differences between treatment groups were assessed by Analysis of Covariance (ANCOVA) on log-transformed values by adjusting for baseline values. Estimates were provided as mean percentage change over baseline (90 % CI). Dose-effect was tested through Spearman's rank correlation. *P*-values are one-tailed. \**P* \< 0.05; Shading = best improvement within dosages. *CMTNS* Charcot-Marie-Tooth Neuropathy Score, *ONLS* Overall Neuropathy Limitations Scale, *6MWT* 6-Minute Walk Test, *9HPT* 9-Hole Peg Test, *CMAP* Amplitudes of Compound Muscle Action Potentials, *MCV* Motor Conduction Velocity, *DML* Distal Motor Latency, *SNAP* Amplitudes of Sensory Nerve Action Potentials, *SCV* Sensitive Conduction VelocityTable 4Response to PXT3003 on efficacy outcomes in HD and in PLI, with comparisons of HD versus PLI (Full Analysis Set, *n* = 80)Mean % of improvementPXT3003 HD versus PLIPLIPXT3003 HDEstimate*P*-value(*n* = 61)(*n* = 19)CMTNS−3.4 (18.4)**5.2 (12.5)**8.0 (0.4;16.2)0.042\*ONLS−7.7 (28.5)**6.8 (18.2)**12.1 (2.0;23.2)0.024\*6MWT (m)7.1 (8.6)**9.9 (6.9)**2.6 (−0.73;6.1)0.0999HPT (s)1.8 (11.1)**6.1 (10.6)**1.2 (−3.4;6.0)0.33Ankle Dorsiflexion (Nm)**33.1 (223.2)**20.4 (64.1)5.5 (−12.8;27.7)0.32Grip (kg)5.1 (17.9)**11.7 (18.1)**6.0 (−1.2;13.7)0.088CMAP (milliV)19.6 (56.5)**64.2 (208.5)**6.6 (−15.8;35.1)0.33MCV (m/s)4.2 (10.9)**9.0 (17.6)**2.5 (−2.4;7.7)0.21DML (ms)3 (15.3)**5 (15.2)**2.2 (−5.1;10.0)0.31SNAP (microV)**15.9 (110.2)**5.2 (69.0)12.0 (−23.9;64.9)0.31SCV (m/s)12.7 (38.0)**30.5 (10.0)**20.1 (2.4;40.8)0.030\*Data are mean % (s.d.) of improvement for HD and for PLI after 12 months. Differences between treatment groups were assessed by Analysis of Covariance (ANCOVA) on log-transformed values by adjusting for baseline values. Estimates were provided as mean percentage change over baseline (90 % CI). *P*-values are one-tailed. \**P* \< 0.05; Shading = best improvement within groups. *CMTNS* Charcot-Marie-Tooth Neuropathy Score, *ONLS* Overall Neuropathy Limitations Scale, *6MWT* 6-Minute Walk Test, *9HPT* 9-Hole Peg Test, *CMAP* Amplitudes of Compound Muscle Action Potentials, *MCV* Motor Conduction Velocity, *DML* Distal Motor Latency, *SNAP* Amplitudes of Sensory Nerve Action Potentials, *SCV* Sensitive Conduction VelocityFig. 4Response to PXT3003 on clinical scales (Full Analysis Set, *n* = 80). Mean % (s.e.m.) of improvement from baseline per group at 12 months for CMTNS (**a**) and ONLS (**b**). Sample sizes: Placebo (*n* = 19), LD (*n* = 21), ID (*n* = 21), HD (*n* = 19)

However this error has no bearing on statistical outcome of the study, the conclusions or text of the manuscript. Correct versions of Tables [3](#Tab1){ref-type="table"}, [4](#Tab2){ref-type="table"} and Fig. [4](#Fig1){ref-type="fig"} can be seen below and Additional file [4](#MOESM1){ref-type="media"} accessed using the link below.

Additional file {#Sec1}
===============

Additional file 4: Table S4.Response to PXT3003 on efficacy outcomes (Full Analysis Set, *n* = 80). Data are mean (s.d.) baseline and final values, and % (s.d.) of improvement for each treatment group and PLI. Differences between treatment groups were assessed by Analysis of Covariance (Ancova) on log-transformed values by adjusting for baseline values. Estimates were provided as mean percentage change over baseline (90 % CI). Dose-effect was tested through Spearman's rank correlation. *P*-values are one-tailed. CMTNS = Charcot-Marie-Tooth Neuropathy Score; ONLS = Overall Neuropathy Limitations Scale; 6MWT = 6-Minute Walk Test; 9HPT = 9-Hole Peg Test; CMAP = Amplitudes of Compound Muscle Action Potentials; MCV = Motor Conduction Velocity; DML = Distal Motor Latency; SNAP = Amplitudes of Sensory Nerve Action Potentials; SCV = Sensitive Conduction Velocity; VAS = Visual Analog Scale; CGI = Clinical Global Impression. (DOC 168 kb)

The online version of the original article can be found under doi:10.1186/s13023-014-0199-0.
